GADICKE ANSBERT — SEC insider filings

SEC reporting owner CIK 1134655. 87 insider filings on record with FilingPulse; latest filed 2026-09-09.

Transaction summary — filings shown

Covers the 50 most recent of 87 filings on record, filed 2021-06-30 to 2026-09-09. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.

By issuer — same filings

Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.

IssuerRole (as filed)FilingsPurchases (P)Sales (S)Other legs
iTeos Therapeutics, Inc. (ITOS)—17—67 legs · 2,504,560 sh · $55,755,0622
Aktis Oncology, Inc. (AKTS)10% owner11 leg · 1,112,777 sh · $20,029,986—6
Cullinan Oncology, Inc. (CGEM)Director10—38 legs · 302,396 sh · $8,850,2842
Entrada Therapeutics, Inc. (TRDA)10% owner61 leg · 100,000 sh · $2,000,00014 legs · 540,669 sh · $4,517,5814
Repare Therapeutics Inc. (RPTX)10% owner2—6 legs · 81,279 sh · $2,736,793—
Werewolf Therapeutics, Inc. (HOWL)—10—29 legs · 1,938,945 sh · $2,227,9633
TCR2 THERAPEUTICS INC. (TCRR)Director, 10% owner2—1 leg · 70,170 sh · $131,9206
Allovir, Inc. (ALVR)Director, 10% owner2——2

Insider filings — GADICKE ANSBERT

FiledFormIssuerReported transactionsSource
2026-09-094Entrada Therapeutics, Inc. (TRDA)
jointly with MPM BioVentures 2014, L.P., EVNIN LUKE, Foley Todd, MPM BioVentures 2014 (B), L.P., MPM Asset Management Investors BV2014 LLC, MPM BioVentures 2014 LLC, MPM BioVentures 2014 GP LLC, MPM BIOVENTURES 2018 (B), L.P., MPM ASSET MANAGEMENT INVESTORS BV2018 LLC
Sale (S): 38,500 @ $7.11 · Sale (S): 192,500 @ $7.41 · Sale (S): 28,837 @ $7.13EDGAR
2026-09-034Entrada Therapeutics, Inc. (TRDA)
jointly with MPM BioVentures 2014, L.P., EVNIN LUKE, Foley Todd, MPM BioVentures 2014 (B), L.P., MPM Asset Management Investors BV2014 LLC, MPM BioVentures 2014 LLC, MPM BioVentures 2014 GP LLC, MPM BIOVENTURES 2018 (B), L.P., MPM ASSET MANAGEMENT INVESTORS BV2018 LLC
Sale (S): 29,088 @ $7.06 · Sale (S): 25,131 @ $7.19 · Sale (S): 32,263 @ $7.17EDGAR
2026-08-314Entrada Therapeutics, Inc. (TRDA)
jointly with MPM BioVentures 2014, L.P., EVNIN LUKE, Foley Todd, MPM BioVentures 2014 (B), L.P., MPM Asset Management Investors BV2014 LLC, MPM BioVentures 2014 LLC, MPM BioVentures 2014 GP LLC, MPM BIOVENTURES 2018 (B), L.P., MPM ASSET MANAGEMENT INVESTORS BV2018 LLC
Sale (S): 38,922 @ $7.20 · Sale (S): 3,733 @ $7.01 · Sale (S): 44,259 @ $6.99EDGAR
2026-08-264Entrada Therapeutics, Inc. (TRDA)
jointly with MPM BioVentures 2014, L.P., EVNIN LUKE, Foley Todd, MPM BioVentures 2014 (B), L.P., MPM Asset Management Investors BV2014 LLC, MPM BioVentures 2014 LLC, MPM BioVentures 2014 GP LLC, MPM BIOVENTURES 2018 (B), L.P., MPM ASSET MANAGEMENT INVESTORS BV2018 LLC
Sale (S): 21,623 @ $7.34 · Sale (S): 26,522 @ $7.54 · Sale (S): 14,569 @ $7.06EDGAR
2026-01-144Aktis Oncology, Inc. (AKTS)
jointly with MPM ASSET MANAGEMENT LLC, Oncology Impact Private Investment Fund 2, L.P.
Conversion (C): 1,314,262 · Conversion (C): 5,914,197 · Conversion (C): 1,577,119 · Purchase (P): 1,112,777 @ $18 · Conversion (C): 5,000,000 (derivative) @ $0 · Conversion (C): 22,500,000 (derivative) @ $0 · +1 moreEDGAR
2025-12-044Werewolf Therapeutics, Inc. (HOWL)
jointly with MPM ONCOLOGY INNOVATIONS FUND LP, UBS Oncology Impact Fund L.P., Oncology Impact Fund (Cayman) Management L.P., MPM BioImpact LLC, MPM Oncology Innovations Fund GP LLC, MPM ASSET MANAGEMENT LLC
Sale (S): 59,277 @ $0.89 · Sale (S): 57,225 @ $0.87 · Sale (S): 83,230 @ $0.97EDGAR
2025-12-014Werewolf Therapeutics, Inc. (HOWL)
jointly with MPM ONCOLOGY INNOVATIONS FUND LP, UBS Oncology Impact Fund L.P., Oncology Impact Fund (Cayman) Management L.P., MPM BioImpact LLC, MPM Oncology Innovations Fund GP LLC, MPM ASSET MANAGEMENT LLC
Sale (S): 60,733 @ $0.98 · Sale (S): 20,277 @ $0.99 · Sale (S): 60,917 @ $0.94EDGAR
2025-11-254Werewolf Therapeutics, Inc. (HOWL)
jointly with MPM ONCOLOGY INNOVATIONS FUND LP, UBS Oncology Impact Fund L.P., Oncology Impact Fund (Cayman) Management L.P., MPM BioImpact LLC, MPM Oncology Innovations Fund GP LLC, MPM ASSET MANAGEMENT LLC
Sale (S): 64,331 @ $0.83 · Sale (S): 88,802 @ $0.98 · Sale (S): 42,533 @ $0.92EDGAR
2025-11-204Werewolf Therapeutics, Inc. (HOWL)
jointly with MPM ONCOLOGY INNOVATIONS FUND LP, UBS Oncology Impact Fund L.P., Oncology Impact Fund (Cayman) Management L.P., MPM BioImpact LLC, MPM Oncology Innovations Fund GP LLC, MPM ASSET MANAGEMENT LLC
Sale (S): 52,627 @ $0.93 · Sale (S): 66,324 @ $0.94 · Sale (S): 41,152 @ $0.89EDGAR
2025-11-174Werewolf Therapeutics, Inc. (HOWL)
jointly with MPM ONCOLOGY INNOVATIONS FUND LP, UBS Oncology Impact Fund L.P., Oncology Impact Fund (Cayman) Management L.P., MPM BioImpact LLC, MPM Oncology Innovations Fund GP LLC, MPM ASSET MANAGEMENT LLC
Sale (S): 90,951 @ $0.98 · Sale (S): 61,640 @ $0.93 · Sale (S): 57,061 @ $0.95EDGAR
2025-11-124Werewolf Therapeutics, Inc. (HOWL)
jointly with MPM ONCOLOGY INNOVATIONS FUND LP, UBS Oncology Impact Fund L.P., Oncology Impact Fund (Cayman) Management L.P., MPM BioImpact LLC, MPM Oncology Innovations Fund GP LLC, MPM ASSET MANAGEMENT LLC
Sale (S): 68,480 @ $1.11 · Sale (S): 48,570 @ $1.18 · Sale (S): 55,810 @ $1.14 · Sale (S): 40,669 @ $1.09EDGAR
2025-11-064Werewolf Therapeutics, Inc. (HOWL)
jointly with MPM ONCOLOGY INNOVATIONS FUND LP, UBS Oncology Impact Fund L.P., Oncology Impact Fund (Cayman) Management L.P., MPM BioImpact LLC, MPM Oncology Innovations Fund GP LLC, MPM ASSET MANAGEMENT LLC
Sale (S): 140,488 @ $1.22 · Sale (S): 47,950 @ $1.22 · Sale (S): 54,452 @ $1.21EDGAR
2025-11-034Werewolf Therapeutics, Inc. (HOWL)
jointly with MPM ONCOLOGY INNOVATIONS FUND LP, UBS Oncology Impact Fund L.P., Oncology Impact Fund (Cayman) Management L.P., MPM BioImpact LLC, MPM Oncology Innovations Fund GP LLC, MPM ASSET MANAGEMENT LLC
Sale (S): 86,936 @ $1.43 · Sale (S): 114,044 @ $1.28 · Sale (S): 94,063 @ $1.29EDGAR
2025-10-294Werewolf Therapeutics, Inc. (HOWL)
jointly with MPM ONCOLOGY INNOVATIONS FUND LP, UBS Oncology Impact Fund L.P., Oncology Impact Fund (Cayman) Management L.P., MPM BioImpact LLC, MPM Oncology Innovations Fund GP LLC, MPM ASSET MANAGEMENT LLC
Sale (S): 72,709 @ $1.72 · Sale (S): 69,068 @ $1.64 · Sale (S): 134,240 @ $1.55EDGAR
2025-05-154iTeos Therapeutics, Inc. (ITOS)
jointly with MPM BioImpact LLC, Oncology Impact Fund (Cayman) Management L.P., UBS Oncology Impact Fund L.P.
Sale (S): 1,031,931 @ $8.06EDGAR
2025-04-304Werewolf Therapeutics, Inc. (HOWL)
jointly with MPM ONCOLOGY INNOVATIONS FUND LP, UBS Oncology Impact Fund L.P., Oncology Impact Fund (Cayman) Management L.P., MPM BioImpact LLC, MPM Oncology Innovations Fund GP LLC, MPM ASSET MANAGEMENT LLC
Option exercise/expiry (X): 50,873 @ $0.09 · Sale (S): 4,386 @ $1.05 · Option exercise/expiry (X): 8,031 (derivative) @ $0 · Option exercise/expiry (X): 42,842 (derivative) @ $0EDGAR
2024-12-124Entrada Therapeutics, Inc. (TRDA)
jointly with MPM BioVentures 2014, L.P., EVNIN LUKE, Foley Todd, MPM BioVentures 2014 (B), L.P., MPM Asset Management Investors BV2014 LLC, MPM BioVentures 2014 LLC, MPM BioVentures 2014 GP LLC, MPM BIOVENTURES 2018 (B), L.P., MPM ASSET MANAGEMENT INVESTORS BV2018 LLC
Sale (S): 22,935 @ $20.77 · Sale (S): 21,787 @ $20.23EDGAR
2023-06-054TCR2 THERAPEUTICS INC. (TCRR)Other (J): 304,001 @ $0 · Other (J): 3,854,963 @ $0 · Other (J): 3,370,982 @ $0EDGAR
2023-05-244TCR2 THERAPEUTICS INC. (TCRR)Option exercise/expiry (X): 178,269 @ $0.74 · Sale (S): 70,170 @ $1.88 · Option exercise/expiry (X): 42,761 (derivative) @ $0 · Option exercise/expiry (X): 135,508 (derivative) @ $0EDGAR
2022-08-014Allovir, Inc. (ALVR)Grant/award (A): 3,253,796 @ $4.61EDGAR
2022-06-234Cullinan Oncology, Inc. (CGEM)Grant/award (A): 16,475 (derivative) @ $0EDGAR
2022-05-194Allovir, Inc. (ALVR)Grant/award (A): 27,500 (derivative) @ $0EDGAR
2022-03-254Cullinan Oncology, Inc. (CGEM)Grant/award (A): 7,800 (derivative) @ $0EDGAR
2022-01-064iTeos Therapeutics, Inc. (ITOS)
jointly with UBS Oncology Impact Fund L.P., BioImpact Capital LLC, Oncology Impact Fund (Cayman) Management L.P.
Sale (S): 158,579 @ $42.05 · Sale (S): 32,396 @ $43.20 · Sale (S): 11,318 @ $45.32 · Sale (S): 12,829 @ $46.47 · Sale (S): 30,347 @ $42.03EDGAR
2021-12-074iTeos Therapeutics, Inc. (ITOS)
jointly with UBS Oncology Impact Fund L.P., BioImpact Capital LLC, Oncology Impact Fund (Cayman) Management L.P.
Sale (S): 29,402 @ $34.68 · Sale (S): 4,047 @ $35.44 · Sale (S): 300 @ $36.26 · Sale (S): 14,173 @ $32.35 · Sale (S): 1,960 @ $33.57 · Sale (S): 850 @ $34.08 · +3 moreEDGAR
2021-12-024iTeos Therapeutics, Inc. (ITOS)
jointly with UBS Oncology Impact Fund L.P., BioImpact Capital LLC, Oncology Impact Fund (Cayman) Management L.P.
Sale (S): 9,809 @ $34.62 · Sale (S): 46,992 @ $35.19 · Sale (S): 10,111 @ $33.82 · Sale (S): 9,131 @ $34.61 · Sale (S): 1,500 @ $35.34 · Sale (S): 49,796 @ $33.74 · +1 moreEDGAR
2021-11-304iTeos Therapeutics, Inc. (ITOS)
jointly with UBS Oncology Impact Fund L.P., BioImpact Capital LLC, Oncology Impact Fund (Cayman) Management L.P.
Sale (S): 10,952 @ $35.49 · Sale (S): 10,258 @ $36.03 · Sale (S): 16,856 @ $34.46 · Sale (S): 500 @ $35.37EDGAR
2021-11-244iTeos Therapeutics, Inc. (ITOS)
jointly with UBS Oncology Impact Fund L.P., BioImpact Capital LLC, Oncology Impact Fund (Cayman) Management L.P.
Other (J): 15,671 @ $0 · Sale (S): 15,575 @ $37.16 · Sale (S): 19,758 @ $37.81 · Sale (S): 32,876 @ $36.21 · Sale (S): 600 @ $36.50 · Sale (S): 8,147 @ $35.20 · +2 moreEDGAR
2021-11-044Entrada Therapeutics, Inc. (TRDA)
jointly with MPM BioVentures 2014, L.P., EVNIN LUKE, MPM BioVentures 2014 (B), L.P., MPM Asset Management Investors BV2014 LLC, MPM BioVentures 2014 LLC, MPM BioVentures 2014 GP LLC, MPM BIOVENTURES 2018 (B), L.P., MPM ASSET MANAGEMENT INVESTORS BV2018 LLC
Conversion (C): 3,816,760 · Conversion (C): 509,024 · Purchase (P): 100,000 @ $20 · Conversion (C): 27,617,675 (derivative) @ $0 · Conversion (C): 3,683,241 (derivative) @ $0EDGAR
2021-10-184iTeos Therapeutics, Inc. (ITOS)
jointly with UBS Oncology Impact Fund L.P., BioImpact Capital LLC, Oncology Impact Fund (Cayman) Management L.P.
Sale (S): 14,882 @ $27.53 · Sale (S): 3,413 @ $28.01 · Sale (S): 10,320 @ $27.14EDGAR
2021-10-144iTeos Therapeutics, Inc. (ITOS)
jointly with UBS Oncology Impact Fund L.P., BioImpact Capital LLC, Oncology Impact Fund (Cayman) Management L.P.
Sale (S): 14,260 @ $27.09 · Sale (S): 35,023 @ $27.13 · Sale (S): 45,719 @ $27.30EDGAR
2021-10-124iTeos Therapeutics, Inc. (ITOS)
jointly with UBS Oncology Impact Fund L.P., BioImpact Capital LLC, Oncology Impact Fund (Cayman) Management L.P.
Sale (S): 1,922 @ $27 · Sale (S): 3,400 @ $27.01 · Sale (S): 81,684 @ $27.24EDGAR
2021-10-054iTeos Therapeutics, Inc. (ITOS)
jointly with UBS Oncology Impact Fund L.P., BioImpact Capital LLC, Oncology Impact Fund (Cayman) Management L.P.
Sale (S): 11,471 @ $27 · Sale (S): 34,659 @ $27.06EDGAR
2021-09-304iTeos Therapeutics, Inc. (ITOS)
jointly with UBS Oncology Impact Fund L.P., BioImpact Capital LLC, Oncology Impact Fund (Cayman) Management L.P.
Sale (S): 32,154 @ $27 · Sale (S): 3,836 @ $27EDGAR
2021-09-274iTeos Therapeutics, Inc. (ITOS)
jointly with UBS Oncology Impact Fund L.P., BioImpact Capital LLC, Oncology Impact Fund (Cayman) Management L.P.
Sale (S): 60,600 @ $27.96 · Sale (S): 1,200 @ $28.38 · Sale (S): 8,221 @ $27.81 · Sale (S): 19,455 @ $27.09EDGAR
2021-09-234iTeos Therapeutics, Inc. (ITOS)
jointly with UBS Oncology Impact Fund L.P., BioImpact Capital LLC, Oncology Impact Fund (Cayman) Management L.P.
Sale (S): 32,858 @ $27.47 · Sale (S): 23,921 @ $27.54EDGAR
2021-09-204Cullinan Oncology, Inc. (CGEM)Sale (S): 432 @ $29.06 · Sale (S): 3,124 @ $29.06EDGAR
2021-09-204iTeos Therapeutics, Inc. (ITOS)
jointly with UBS Oncology Impact Fund L.P., BioImpact Capital LLC, Oncology Impact Fund (Cayman) Management L.P.
Sale (S): 35,565 @ $28.47 · Sale (S): 76,473 @ $28.82 · Sale (S): 17,743 @ $27.03 · Sale (S): 22,930 @ $27.84EDGAR
2021-09-164Cullinan Oncology, Inc. (CGEM)Sale (S): 982 @ $29.17 · Sale (S): 7,106 @ $29.17 · Sale (S): 888 @ $29.16 · Sale (S): 6,425 @ $29.16EDGAR
2021-09-164iTeos Therapeutics, Inc. (ITOS)
jointly with UBS Oncology Impact Fund L.P., BioImpact Capital LLC, Oncology Impact Fund (Cayman) Management L.P.
Sale (S): 30,018 @ $27.50 · Sale (S): 6,063 @ $27.99 · Sale (S): 38,677 @ $27.79 · Sale (S): 1,659 @ $28.15EDGAR
2021-09-134Cullinan Oncology, Inc. (CGEM)Sale (S): 1,898 @ $29.35 · Sale (S): 13,727 @ $29.35 · Sale (S): 820 @ $29.04 · Sale (S): 5,931 @ $29.04 · Sale (S): 497 @ $29.10 · Sale (S): 3,595 @ $29.10EDGAR
2021-09-134iTeos Therapeutics, Inc. (ITOS)
jointly with UBS Oncology Impact Fund L.P., BioImpact Capital LLC, Oncology Impact Fund (Cayman) Management L.P.
Sale (S): 38,028 @ $28.97 · Sale (S): 11,313 @ $27.86 · Sale (S): 11,330 @ $28.73 · Sale (S): 35,785 @ $27.64EDGAR
2021-09-084Cullinan Oncology, Inc. (CGEM)Sale (S): 1,760 @ $29.60 · Sale (S): 12,731 @ $29.60 · Sale (S): 3,465 @ $29.04 · Sale (S): 25,067 @ $29.04 · Sale (S): 1,499 @ $29.11 · Sale (S): 10,842 @ $29.11EDGAR
2021-09-084iTeos Therapeutics, Inc. (ITOS)
jointly with UBS Oncology Impact Fund L.P., BioImpact Capital LLC, Oncology Impact Fund (Cayman) Management L.P.
Sale (S): 50,996 @ $29.18 · Other (J): 31,340 @ $0 · Sale (S): 18,663 @ $28.61 · Sale (S): 1,573 @ $29.10EDGAR
2021-09-024Cullinan Oncology, Inc. (CGEM)Sale (S): 177 @ $29.43 · Sale (S): 1,285 @ $29.43 · Sale (S): 215 @ $30.14 · Sale (S): 1,553 @ $30.14 · Sale (S): 790 @ $29.47 · Sale (S): 5,714 @ $29.47 · +2 moreEDGAR
2021-08-314Cullinan Oncology, Inc. (CGEM)Sale (S): 1,846 @ $29.09 · Sale (S): 13,357 @ $29.09 · Sale (S): 4,285 @ $29.30 · Sale (S): 31,001 @ $29.30EDGAR
2021-08-254Cullinan Oncology, Inc. (CGEM)Sale (S): 7,376 @ $29.11 · Sale (S): 53,359 @ $29.11 · Sale (S): 7,025 @ $29.48 · Sale (S): 50,882 @ $29.48 · Sale (S): 237 @ $29.09 · Sale (S): 1,713 @ $29.09EDGAR
2021-08-124Cullinan Oncology, Inc. (CGEM)Sale (S): 347 @ $29.05 · Sale (S): 2,510 @ $29.05EDGAR
2021-07-134Repare Therapeutics Inc. (RPTX)Sale (S): 4,067 @ $33.06 · Sale (S): 57,301 @ $33.58 · Sale (S): 711 @ $34.10EDGAR
2021-06-304Repare Therapeutics Inc. (RPTX)Sale (S): 13,800 @ $34.06 · Sale (S): 2,700 @ $34.82 · Sale (S): 2,700 @ $33.29EDGAR

FilingPulse's Form 4 archive currently extends back to 2020-09-21 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.

Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1134655 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs